BioRestorative Therapies (BRTX) Current Deferred Revenue (2014 - 2025)
BioRestorative Therapies' (BRTX) quarterly Current Deferred Revenue came in at $150000.0 in Q1 2025, up 85.87% on a QoQ basis from $80700.0 in Q2 2024.
BioRestorative Therapies (BRTX) Current Deferred Revenue (2014 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 4 years of Current Deferred Revenue data on file, last reported at $150000.0 in Q1 2025.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $150000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $150000.0 (changed N/A YoY) and the FY2014 annual result came in at $164349.0, changed N/A from the prior year.
- Current Deferred Revenue rose to $150000.0 in Q1 2025, from $80700.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $150000.0 in Q1 2025 to a low of $80700.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 150,000.00 |
| Jun 30, 2024 | 80,700.00 |
| Sep 30, 2015 | 101,527.00 |
| Jun 30, 2015 | 114,118.00 |
| Mar 31, 2015 | 210,882.00 |
| Dec 31, 2014 | 164,349.00 |
| Sep 30, 2014 | 154,662.00 |
| Jun 30, 2014 | 224,975.00 |
| Mar 31, 2014 | 89,063.00 |